A Study to Evaluate the Efficacy and Safety of Co-administrated BR1018B and BR1018C
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 151 participants.
Also called NCT06165250
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 151 participants
- Registry
-
NCT06165250
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT06165250. Randomized; double masking; primary purpose treatment. Start 2024-04-17 (actual); primary completion 2025-11-11 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Evaluate the Efficacy and Safety of Co-administrated BR1018B and BR1018C
- Condition
- Essential Hypertension
- Condition
- Primary Hypercholesterolemia
- Intervention (Drug)
- BR1018A
- Intervention (Drug)
- BR1018A-1
- Intervention (Drug)
- BR1018B
- Intervention (Drug)
- BR1018B-1
- Intervention (Drug)
- BR1018C
- Intervention (Drug)
- BR1018C-1
- Lead sponsor
- Boryung Pharmaceutical Co., Ltd
Record details
- Record id
cardio:ct-nct06165250- Content hash
7f073b37fbfa0e4e1ca463d06d6067b01987a9b33288ccef2b94841b9b253b85